ORUM - Asset Resilience Ratio

Latest as of March 2025: 82.74%

ORUM (475830) has an Asset Resilience Ratio of 82.74% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ORUM (475830) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩158.45 Billion
≈ $107.38 Million USD Cash + Short-term Investments

Total Assets

₩191.52 Billion
≈ $129.79 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how ORUM's Asset Resilience Ratio has changed over time. See 475830 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down ORUM's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ORUM (475830) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩7.44 Billion 3.88%
Short-term Investments ₩151.02 Billion 78.85%
Total Liquid Assets ₩158.45 Billion 82.74%

Asset Resilience Insights

  • Very High Liquidity: ORUM maintains exceptional liquid asset reserves at 82.74% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ORUM Industry Peers by Asset Resilience Ratio

Compare ORUM's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for ORUM (2022–2024)

The table below shows the annual Asset Resilience Ratio data for ORUM.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 76.51% ₩117.70 Billion
≈ $79.76 Million
₩153.84 Billion
≈ $104.25 Million
-1.78pp
2023-12-31 78.29% ₩126.66 Billion
≈ $85.83 Million
₩161.78 Billion
≈ $109.64 Million
+21.51pp
2022-12-31 56.78% ₩12.09 Billion
≈ $8.19 Million
₩21.28 Billion
≈ $14.42 Million
--
pp = percentage points

About ORUM

KQ:475830 Korea Biotechnology
Market Cap
$424.14K
₩625.87 Million KRW
Market Cap Rank
#30894 Global
#2045 in Korea
Share Price
₩64100.00
Change (1 day)
-8.43%
52-Week Range
₩17180.00 - ₩143700.00
All Time High
₩143700.00
About

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more